Savara Inc (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Savara Inc (NASDAQ:SVRA) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $9.86.

A number of analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective for the company. Evercore ISI restated an “in-line” rating and set a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright cut their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th.

Savara Price Performance

SVRA opened at $3.14 on Wednesday. The firm has a market capitalization of $538.88 million, a PE ratio of -7.30 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business’s 50-day moving average is $3.39 and its two-hundred day moving average is $3.92. Savara has a 1 year low of $2.82 and a 1 year high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). Research analysts anticipate that Savara will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Savara

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by corporate insiders.

Institutional Trading of Savara

Large investors have recently made changes to their positions in the company. Choreo LLC acquired a new stake in Savara during the 2nd quarter worth $59,000. DRW Securities LLC acquired a new position in Savara during the second quarter worth about $62,000. Virtu Financial LLC purchased a new stake in Savara during the 3rd quarter valued at about $67,000. Principal Financial Group Inc. raised its holdings in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after purchasing an additional 18,534 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.